Diamyd Medical exercises all of its warrants in NextCell Pharma

Diamyd Medical invests another SEK 1.5 million in the stem cell company NextCell Pharma AB by exercising all of the Company’s warrants of the TO1 Series in NextCell Pharma. Diamyd Medical holds 296,800 warrants, corresponding to approximately 10.4 % of the total number of outstanding warrants.Diamyd Medical is one of the main shareholders of NextCell Pharma, with a shareholding of approximately 13.8%. At full utilization rate of all outstanding warrants of series TO 1, a total of 2 860 940, Diamyd Medical will after the warrants have been converted to shares, hold approximately 12.9% of